Simile Funding: How Much It Raised, Its Valuation & Investors

Simile raised $200 million in a Series B round at a $2 billion valuation, announced July 30, 2026 and led by Greenoaks, with Index Ventures co-leading. The round arrives just five months after the company's $100 million Series A, roughly doubling its valuation in that span.

Here's the full breakdown of the raise, who backed it, and what the fast follow-on says about investor appetite for AI-driven market research.

What is Simile?

Simile builds AI agents that simulate user behavior and predict how real consumers respond to products, messaging and designs. The pitch is machine-speed market research: replacing slow, expensive focus groups and surveys with synthetic respondents that can be tested against at scale and in minutes rather than weeks. For product and marketing teams used to waiting weeks for survey results or recruiting panels for a focus group, that speed is the entire value proposition — feedback fast enough to fold into an iteration cycle instead of arriving after decisions have already shipped.

The raise: $200M Series B

The headline numbers:

• Amount: $200 million
• Round: Series B
• Valuation: $2 billion
• Announced: July 30, 2026
• Lead investor: Greenoaks
• Co-lead: Index Ventures

Simile's Series A closed in January 2026 at $100 million. Going to a $2 billion valuation on a $200 million round just five months later — roughly doubling in value over that stretch — is one of the faster valuation climbs among AI startups in 2026, and it suggests investors saw strong early traction rather than waiting for a longer track record.

Who invested in Simile?

The round was led by Greenoaks, with Index Ventures co-leading. Additional participants included:

• Hanabi
• Bain Capital
• CVS Health

CVS Health's participation stands out as a strategic rather than purely financial investment — a major healthcare and retail company backing a synthetic market-research platform suggests direct interest in applying the technology to its own consumer research.

What Simile will do with the money

Simile said the funding will go toward product development and go-to-market expansion — the standard playbook for a company scaling fast after proving out an early product with a smaller customer base. Landing a strategic investor like CVS Health alongside that capital gives Simile both funding and a foothold for expanding into healthcare-adjacent research use cases as it builds out its go-to-market team.

Why it matters

Simile's rapid follow-on round is worth watching for a few reasons:

1. Investors are betting fast on synthetic market research. A 2x valuation jump in five months, tracked alongside other rapid raises in the biggest funding rounds of 2026, shows how quickly capital can move once a category shows early signs of working.
2. A strategic healthcare investor signals cross-industry demand. CVS Health's participation hints that synthetic user research could extend well beyond consumer tech and retail into pharma, healthcare and other regulated industries where traditional research is slow and costly.
3. The core bet is still unproven. Whether AI agents can genuinely substitute for human judgment in understanding consumer behavior is an open question — but the funding pace suggests investors are willing to bet the answer is yes well before that question is fully settled.

Source: TechCrunch — Synthetic user startup Simile raises $200M at $2B valuation, 5 months after $100M Series A

Following AI funding? Wortins tracks the biggest raises, valuations, and acquisitions daily in the AI Funding Tracker.